Sequent Scientific Ltd (VIYASH) Q1FY27 Concall Summary - Jun-2026 Qtr
Performance Overview
- The company reported a strong quarter, with management emphasizing consistent quarter-over-quarter performance, highlighting that the growth is sustainable and not a one-off event.
- Significant improvement was seen in profitability, with EBITDA margins expanding by 530 basis points year-on-year, driven by a shift towards backward-integrated, complex products and disciplined cost management.
- The balance sheet has strengthened considerably, with net debt reducing to INR 86 crores, bringing the net debt to EBITDA ratio down to 0.1x from nearly 1.0x a year ago, positioning the company as virtually debt-free on a net basis.
- The company is actively investing for future growth, both organically through R&D and manufacturing expansions, and inorganically with the strategic acquisition of Bioforlife in Italy to bolster its companion animal business.
- All business segments are showing positive momentum, with strong growth in the animal health formulations business across all regions, a significant turnaround in the US human formulations business, and a robust order pipeline for the API business expected in the upcoming quarter.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.